We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Hologic's Diagnostics Arm Set for Long-Term Upside: What's Behind It?
Read MoreHide Full Article
Key Takeaways
{\"0\":\"HOLX\'s Diagnostics unit grew 0.9% Y/Y in Q3, pressured by USAID cuts and China market challenges.\",\"1\":\"Hologic\'s BV, CV/TV assay and Panther Fusion platform gains are fueling Diagnostics segment momentum.\",\"2\":\"Biotheranostics\' Breast Cancer Index test sees strong uptake, expanding HOLX\'s oncology footprint.\"}
Hologic’s (HOLX - Free Report) Diagnostics unit, the largest by revenues, has been the most impacted by geopolitical headwinds this year. Cuts in USAID funding have affected its HIV testing business in Africa, while a challenging operating environment in China has weighed on its Cytology business. As a result, Diagnostics posted just 0.9% year-over-year reported growth in the third quarter of fiscal 2025. Despite these hurdles, the underlying growth drivers in the segment continue to remain strong.
One is the BV, CV/TV assay, which has become Hologic’s second-largest assay globally after shifting from a primarily lab-developed test (LDT) approved in 2019 to an in-vitro diagnostics (IVD) test on the high-throughput Panther instrument. The company is working to reach the estimated 60% of U.S. women who are not tested when they experience vaginitis, applying the same approach it uses to expand sexually transmitted infection (STI) testing.
Additionally, Panther Fusion, an add-on module to the base Panther platform, is gaining nice traction this year as customers adopt more menus. The system uses PCR chemistry to run Hologic’s suite of respiratory assays, including influenza, while offering an expanded IVD menu and Open Access functionality for LDTs. Open Access testing kits contributed to Fusion’s solid growth in the fiscal third quarter. Over the next several years, Hologic plans to broaden the menu by launching an IVD test for GI and hospital-acquired infections, positioning the sidecar to play a key role in future Diagnostics growth.
The company is also currently in the early stages of its Biotheranostics opportunity. Acquired in 2021, the asset marked Hologic’s entry into the lab-based oncology space, an expanding and longtime area of interest. Biotheranostics’ Breast Cancer Index test — the only commercially available test validated to inform the decision regarding extended endocrine therapy — continues to see strong adoption.
Latest Updates From Hologic’s Diagnostics Peers
Abbott’s (ABT - Free Report) Diagnostics sales declined 1.5% in the second quarter of 2025, mainly due to the year-over-year decrease in COVID-19 testing sales and the impact of volume-based procurement programs in China. Together, these are expected to weigh on ABT’s full-year Diagnostics sales growth by around $700 million or 750 basis points. Excluding China, Abbott’s Core Lab Diagnostics grew 8%, reflecting strong underlying demand in the global markets.
Danaher’s (DHR - Free Report) core sales growth in the molecular diagnostics business witnessed growth in the second quarter of 2025, as gains in non-respiratory testing more than offset declines in core sales of respiratory tests. Danaher also announced a new partnership with AstraZeneca to develop diagnostic tools that identify patients most likely to benefit from precision medicine treatments. This collaboration is leveraging the newly launched Danaher Centers to enable precision medicine to streamline the end-to-end development process.
HOLX Stock Performance, Valuation and Estimates
Year to date, Hologic shares have declined 5.8% compared with the industry’s 11.7% fall.
Image Source: Zacks Investment Research
Hologic is trading at a forward five-year price-to-earnings of 15.05X, lower than the industry average of 27.49X. The stock carries a Value Score of B at present.
Image Source: Zacks Investment Research
See how analysts are projecting Hologic’s EPS for fiscal 2025 and 2026.
Image: Bigstock
Hologic's Diagnostics Arm Set for Long-Term Upside: What's Behind It?
Key Takeaways
Hologic’s (HOLX - Free Report) Diagnostics unit, the largest by revenues, has been the most impacted by geopolitical headwinds this year. Cuts in USAID funding have affected its HIV testing business in Africa, while a challenging operating environment in China has weighed on its Cytology business. As a result, Diagnostics posted just 0.9% year-over-year reported growth in the third quarter of fiscal 2025. Despite these hurdles, the underlying growth drivers in the segment continue to remain strong.
One is the BV, CV/TV assay, which has become Hologic’s second-largest assay globally after shifting from a primarily lab-developed test (LDT) approved in 2019 to an in-vitro diagnostics (IVD) test on the high-throughput Panther instrument. The company is working to reach the estimated 60% of U.S. women who are not tested when they experience vaginitis, applying the same approach it uses to expand sexually transmitted infection (STI) testing.
Additionally, Panther Fusion, an add-on module to the base Panther platform, is gaining nice traction this year as customers adopt more menus. The system uses PCR chemistry to run Hologic’s suite of respiratory assays, including influenza, while offering an expanded IVD menu and Open Access functionality for LDTs. Open Access testing kits contributed to Fusion’s solid growth in the fiscal third quarter. Over the next several years, Hologic plans to broaden the menu by launching an IVD test for GI and hospital-acquired infections, positioning the sidecar to play a key role in future Diagnostics growth.
The company is also currently in the early stages of its Biotheranostics opportunity. Acquired in 2021, the asset marked Hologic’s entry into the lab-based oncology space, an expanding and longtime area of interest. Biotheranostics’ Breast Cancer Index test — the only commercially available test validated to inform the decision regarding extended endocrine therapy — continues to see strong adoption.
Latest Updates From Hologic’s Diagnostics Peers
Abbott’s (ABT - Free Report) Diagnostics sales declined 1.5% in the second quarter of 2025, mainly due to the year-over-year decrease in COVID-19 testing sales and the impact of volume-based procurement programs in China. Together, these are expected to weigh on ABT’s full-year Diagnostics sales growth by around $700 million or 750 basis points. Excluding China, Abbott’s Core Lab Diagnostics grew 8%, reflecting strong underlying demand in the global markets.
Danaher’s (DHR - Free Report) core sales growth in the molecular diagnostics business witnessed growth in the second quarter of 2025, as gains in non-respiratory testing more than offset declines in core sales of respiratory tests. Danaher also announced a new partnership with AstraZeneca to develop diagnostic tools that identify patients most likely to benefit from precision medicine treatments. This collaboration is leveraging the newly launched Danaher Centers to enable precision medicine to streamline the end-to-end development process.
HOLX Stock Performance, Valuation and Estimates
Year to date, Hologic shares have declined 5.8% compared with the industry’s 11.7% fall.
Image Source: Zacks Investment Research
Hologic is trading at a forward five-year price-to-earnings of 15.05X, lower than the industry average of 27.49X. The stock carries a Value Score of B at present.
Image Source: Zacks Investment Research
See how analysts are projecting Hologic’s EPS for fiscal 2025 and 2026.
Image Source: Zacks Investment Research
HOLX stock currently carries a Zacks Rank #3 (Hold).You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.